SUMO2, human recombinant protein
SUMO-2, Ubiquitin-like protein SMT3B, SMT3 homolog 2, Sentrin-2, HSMT3, SUMO-3, Sentrin2, SUMO2, SMT
|Calculated MW||11.6 kDa|
|Other Names||SUMO-2, Ubiquitin-like protein SMT3B, SMT3 homolog 2, Sentrin-2, HSMT3, SUMO-3, Sentrin2, SUMO2, SMT3H2, MGC117191.|
|Storage||-80°C; In 50 mM HEPES, pH 8.0, plus 150 mM NaCl, 1 mM DTT.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation and transcriptional regulation. SUMO1 functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. Still, unlike ubiquitin which targets proteins for degradation, SUMO-2 is involved in a variety of Cellular processes, for example nuclear transport, transcriptional regulation, apoptosis, and protein stability. The active recombinant SUMO-2 is derived from the precursor pro-SUMO-2 (Accession # NM_006937). Human SUMO-2 shares 44% and 86% identity with SUMO-1 and SUMO-3 respectively. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1, RANBP2, PML, p53, Sp100, HIPK2) but there are also cytosolic substrates (IκBα, GLUT1, GLUT4). SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation, transcriptional regulation, apoptosis and protein stability.
Mannen H.,et al.Biochem. Biophys. Res. Commun. 222:178-180(1996).
Lapenta V.,et al.Genomics 40:362-367(1997).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Zody M.C.,et al.Nature 440:1045-1049(2006).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at email@example.com.